Henrichfreise B, Wiegand I, Pfister W, Wiedemann B
Institute for Medical Microbiology, Immunology and Parasitology, Pharmaceutical Microbiology Unit, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany.
Antimicrob Agents Chemother. 2007 Nov;51(11):4062-70. doi: 10.1128/AAC.00148-07. Epub 2007 Sep 17.
In this study, we analyzed the mechanisms of multiresistance for 22 clinical multiresistant and clonally different Pseudomonas aeruginosa strains from Germany. Twelve and 10 strains originated from cystic fibrosis (CF) and non-CF patients, respectively. Overproduction of the efflux systems MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM was studied. Furthermore, loss of OprD, alterations in type II topoisomerases, AmpC overproduction, and the presence of 25 acquired resistance determinants were investigated. The presence of a hypermutation phenotype was also taken into account. Besides modifications in GyrA (91%), the most frequent mechanisms of resistance were MexXY-OprM overproduction (82%), OprD loss (82%), and AmpC overproduction (73%). Clear differences between strains from CF and non-CF patients were found: numerous genes coding for aminoglycoside-modifying enzymes and located, partially in combination with beta-lactamase genes, in class 1 integrons were found only in strains from non-CF patients. Furthermore, multiple modifications in type II topoisomerases conferring high quinolone resistance levels and overexpression of MexAB-OprM were exclusively detected in multiresistant strains from non-CF patients. Correlations of the detected phenotypes and resistance mechanisms revealed a great impact of efflux pump overproduction on multiresistance in P. aeruginosa. Confirming previous studies, we found that additional, unknown chromosomally mediated resistance mechanisms remain to be determined. In our study, 11 out of 12 strains and 3 out of 10 strains from CF patients and non-CF patients, respectively, were hypermutable. This extremely high proportion of mutator strains should be taken into consideration for the treatment of multiresistant P. aeruginosa.
在本研究中,我们分析了来自德国的22株临床多重耐药且克隆型不同的铜绿假单胞菌菌株的多重耐药机制。其中12株和10株菌株分别源自囊性纤维化(CF)患者和非CF患者。我们研究了外排系统MexAB - OprM、MexCD - OprJ、MexEF - OprN和MexXY - OprM的过表达情况。此外,还研究了OprD缺失、II型拓扑异构酶的改变、AmpC过表达以及25种获得性耐药决定因素的存在情况。同时也考虑了高突变表型的存在。除了GyrA修饰(91%)外,最常见的耐药机制是MexXY - OprM过表达(82%)、OprD缺失(82%)和AmpC过表达(73%)。我们发现CF患者和非CF患者的菌株之间存在明显差异:仅在非CF患者的菌株中发现了许多编码氨基糖苷修饰酶的基因,这些基因部分与β - 内酰胺酶基因一起位于1类整合子中。此外,仅在非CF患者的多重耐药菌株中检测到II型拓扑异构酶的多种修饰导致高喹诺酮耐药水平以及MexAB - OprM的过表达。检测到的表型与耐药机制之间的相关性表明,外排泵过表达对铜绿假单胞菌的多重耐药有很大影响。正如先前研究所证实的,我们发现仍有待确定其他未知的染色体介导的耐药机制。在我们的研究中,CF患者的12株菌株中有11株以及非CF患者的10株菌株中有3株是高突变的。在治疗多重耐药铜绿假单胞菌时应考虑到这种极高比例的突变菌株。